Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Ascentage Pharma Group International ( (HK:6855) ).
Ascentage Pharma announced that data from two of its clinical studies will be presented at the 2025 ASCO Annual Meeting, a prominent event in the oncology field. The presentations will feature results from studies on lisaftoclax and alrizomadlin, highlighting the company’s advancements in cancer treatment and potentially enhancing its position in the oncology market.
More about Ascentage Pharma Group International
Ascentage Pharma Group International is a biopharmaceutical company focused on developing therapies for cancer, hepatitis B, and age-related diseases. The company specializes in apoptosis-targeted drugs, with key products including Bcl-2 selective inhibitors and MDM2-p53 inhibitors.
YTD Price Performance: -5.61%
Average Trading Volume: 4,433,082
Technical Sentiment Signal: Sell
Current Market Cap: HK$14.81B
For a thorough assessment of 6855 stock, go to TipRanks’ Stock Analysis page.